New Tepezza Data to be Presented at the American Academy of Ophthalmology 2021 Annual Meeting

Horizon Therapeutics announced new Tepezza data will be presented at the American Academy of Ophthalmology Annual Meeting in New Orleans and virtually, Nov. 12-15, 2021. Tepezza is the first and only medicine approved by the FDA for the treatment of TED, a serious, progressive and potentially vision-threatening rare autoimmune disease.¹

Data being presented at AAO 2021 include:

TEPEZZA data:

• Title: Real-World Adherence with Teprotumumab in TED
  • Session: PO026, R. Douglas
  • Date: Sunday, Nov. 14, 9:15 a.m. CT (e-poster also available on demand)

• Title: Teprotumumab Efficacy in TED Patients with Low Inflammation as Measured by Clinical Activity Score
  • Session: PA059, R. Douglas
  • Date: Monday, Nov. 15, 10:45 a.m. CT (e-poster also available on demand)

TED data:

• Title: TED and Healthcare Resource Utilization
  • Session: PO028, A. Kossler
  • Date: Sunday, Nov. 14, 9:37 a.m. CT (e-poster also available on demand)

• Title: Development of Health State Utilities for TED
  • Session: PO295, K. Cockerham
  • Date: On demand (e-poster)

Horizon will also host a product theater on Sunday, Nov. 14 at 4:10 p.m. CT titled “Impact of Tepezza (teprotumumab-trbw): Real-world Cases in Thyroid Eye Disease” featuring Andrew R. Harrison, M.D., Director of Oculoplastic and Orbital Surgery and Co-Director, Center for Thyroid Eye Disease, University of Minnesota.